<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02302365</url>
  </required_header>
  <id_info>
    <org_study_id>CTS-5043</org_study_id>
    <nct_id>NCT02302365</nct_id>
  </id_info>
  <brief_title>Data Collection of Routine Clinical Use With the Spectra Optia® Apheresis System for White Blood Cell Depletion</brief_title>
  <acronym>WBCD</acronym>
  <official_title>Multicenter, Retrospective Data Collection of Routine Clinical Use With the Spectra Optia® Apheresis System for White Blood Cell Depletion</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Terumo BCT</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Terumo BCT</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a multicenter, retrospective data collection of routine clinical use with the
      Spectra Optia® apheresis system for white blood cell depletion.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The goal of this study is to gather a broader knowledge and information from routine clinical
      use on the performance and safety of white blood cell depletion procedures with the Spectra
      Optia® apheresis system.

      In order to do so, retrospective data on white blood cell depletion procedures with the
      Spectra Optia® apheresis system done in routine use in 3 different centers will be collected
      and analyzed.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2014</start_date>
  <completion_date type="Actual">April 2015</completion_date>
  <primary_completion_date type="Actual">April 2015</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Percent Change in White Blood Cell Count in Patient Following Apheresis Procedure</measure>
    <time_frame>immediately after procedure: on average this will be within 15minutes after the end of the procedure</time_frame>
    <description>(WBCpre - WBCpost) / WBCpre x 100%</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Collection Efficiency (CE) for WBC (or Percent of Processed WBCs) Achieved by Spectra Optia.</measure>
    <time_frame>immediately: on average this will be within 15minutes after the end of the procedure</time_frame>
    <description>(WBC/µL product x product volume) / ((WBCpre + WBCpost) / 2) x total processed blood volume)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>Participants were followed for the duration of the procedure and for up to 2 hours after the procedure, an average of 6 hours.</time_frame>
  </primary_outcome>
  <other_outcome>
    <measure>Patient's WBC Count Pre-depletion Procedure</measure>
    <time_frame>Prior to Each Spectra Optia Apheresis Procedure</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Patient's WBC Count Post-depletion Procedure</measure>
    <time_frame>Participants were followed for the duration of the procedure and for up to 2 hours after the procedure, an average of 6 hours.</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Patient's Platelet Count Pre-depletion Procedure</measure>
    <time_frame>Prior to Each Spectra Optia Apheresis Procedure</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Patient's Platelet Count Post-depletion Procedure</measure>
    <time_frame>Participants were followed for the duration of the procedure and for up to 2 hours after the procedure, an average of 6 hours.</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Whole Blood Processed (mL)</measure>
    <time_frame>Participants were followed for the duration of the procedure and for up to 2 hours after the procedure, an average of 6 hours.</time_frame>
    <description>volume of patient's blood processed during the apheresis procedure</description>
  </other_outcome>
  <other_outcome>
    <measure>Average Inlet Flow Rate</measure>
    <time_frame>Participants were followed for the duration of the procedure and for up to 2 hours after the procedure, an average of 6 hours.</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Procedure Duration</measure>
    <time_frame>Participants were followed for the duration of the procedure and for up to 2 hours after the procedure, an average of 6 hours.</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Platelet Change (% Change)</measure>
    <time_frame>Participants were followed for the duration of the procedure and for up to 2 hours after the procedure, an average of 6 hours.</time_frame>
    <description>% change in patient's pre and post-depletion procedure platelet counts</description>
  </other_outcome>
  <other_outcome>
    <measure>Waste Bag Volume</measure>
    <time_frame>Post each Spectra Optia Apheresis Procedure</time_frame>
    <description>Volume of the depletion product</description>
  </other_outcome>
  <enrollment type="Actual">43</enrollment>
  <condition>Leukocytosis</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Spectra Optia® Apheresis System</intervention_name>
    <description>White Blood Cell Depletion</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients who have undergone white blood cell depletion via the Spectra Optia Apheresis
        System which is likely to include patients with severe leukocytosis in acute leukemia
        (acute myeloid leukemia, acute lymphoblastic leukemia, or in chronic myelogenous leukemia
        or to prevent tumor lysis syndrome.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients having received a minimum of 1 white blood cell depletion procedure via the
             Spectra Optia Apheresis System

        Exclusion Criteria:
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Raymond P Goodrich, PhD</last_name>
    <role>Study Director</role>
    <affiliation>VP, Scientific and Clinical Affairs; Chief Science Officer-BBT</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UZ Gasthuisberg</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute for Transfusion Medicine and Immunohaematology, German Red Cross Blood Donor Service Baden-Württemberg-Hessen gGmbH, Johann-Wolfgang-Goethe-University Hospital</name>
      <address>
        <city>Frankfurt/Main</city>
        <zip>60528</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Szent Istvan and Szent Laszlo Hospital of Budapest</name>
      <address>
        <city>Budapest</city>
        <zip>1097</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Germany</country>
    <country>Hungary</country>
  </location_countries>
  <verification_date>November 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 18, 2014</study_first_submitted>
  <study_first_submitted_qc>November 24, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 27, 2014</study_first_posted>
  <results_first_submitted>November 12, 2015</results_first_submitted>
  <results_first_submitted_qc>February 3, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 3, 2016</results_first_posted>
  <last_update_submitted>February 3, 2016</last_update_submitted>
  <last_update_submitted_qc>February 3, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 3, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>white blood cell depletion</keyword>
  <keyword>apheresis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukocytosis</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Subjects Who Received a Minimum of 1 WBCD Procedure u</title>
          <description>Eligible subjects had received a minimum of 1 WBCD procedure using the Spectra Optia Apheresis System</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="43">Data were collected from 58 WBCD procedures performed in 43 subjects - Full and Safety Analysis Sets</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="41">The Per-protocol Analysis Set comprised 54 procedures performed in 41 subjects</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Eligible subjects had received a minimum of 1 WBCD procedure using the Spectra Optia Apheresis System.</population>
      <group_list>
        <group group_id="B1">
          <title>Subjects Who Received a Minimum of 1 WBCD Procedure u</title>
          <description>Eligible subjects had received a minimum of 1 WBCD procedure using the Spectra Optia Apheresis System</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="43"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="51.9" spread="17.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Belgium</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Germany</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hungary</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight</title>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="73.2" spread="16.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Height</title>
          <units>cm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="170.9" spread="10.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Total Blood Volume</title>
          <units>Liters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4.7" spread="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percent Change in White Blood Cell Count in Patient Following Apheresis Procedure</title>
        <description>(WBCpre - WBCpost) / WBCpre x 100%</description>
        <time_frame>immediately after procedure: on average this will be within 15minutes after the end of the procedure</time_frame>
        <population>Full and Safety Analysis Sets. Data were collected for 43 subjects who underwent a total of 58 WBCD procedures. One subject terminated her first procedure prematurely and therefore did not have post-procedure data. Percent decrease in white blood cell count in patient following apheresis procedure measured for 57 procedures in 43 subjects.</population>
        <group_list>
          <group group_id="O1">
            <title>Subjects Who Received a Minimum of 1 WBCD Procedure u</title>
            <description>Eligible subjects had received a minimum of 1 WBCD procedure using the Spectra Optia Apheresis System</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change in White Blood Cell Count in Patient Following Apheresis Procedure</title>
          <description>(WBCpre - WBCpost) / WBCpre x 100%</description>
          <population>Full and Safety Analysis Sets. Data were collected for 43 subjects who underwent a total of 58 WBCD procedures. One subject terminated her first procedure prematurely and therefore did not have post-procedure data. Percent decrease in white blood cell count in patient following apheresis procedure measured for 57 procedures in 43 subjects.</population>
          <units>% change in subject's WBC count</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="43"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>procedures</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="57"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-54.7" spread="21.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Collection Efficiency (CE) for WBC (or Percent of Processed WBCs) Achieved by Spectra Optia.</title>
        <description>(WBC/µL product x product volume) / ((WBCpre + WBCpost) / 2) x total processed blood volume)</description>
        <time_frame>immediately: on average this will be within 15minutes after the end of the procedure</time_frame>
        <population>The CE of the WBCD procedures as measured from the waste bag (depletion product) contents was 58.7% (SD: 16.1%) across Sites 2 and 3. WBC counts were not available from the waste bags for subjects treated at Site 1.</population>
        <group_list>
          <group group_id="O1">
            <title>Subjects Who Received a Minimum of 1 WBCD Procedure u</title>
            <description>Eligible subjects had received a minimum of 1 WBCD procedure using the Spectra Optia Apheresis System</description>
          </group>
        </group_list>
        <measure>
          <title>Collection Efficiency (CE) for WBC (or Percent of Processed WBCs) Achieved by Spectra Optia.</title>
          <description>(WBC/µL product x product volume) / ((WBCpre + WBCpost) / 2) x total processed blood volume)</description>
          <population>The CE of the WBCD procedures as measured from the waste bag (depletion product) contents was 58.7% (SD: 16.1%) across Sites 2 and 3. WBC counts were not available from the waste bags for subjects treated at Site 1.</population>
          <units>percent of processed WBCs</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>procedures</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="43"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58.7" spread="16.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Adverse Events</title>
        <time_frame>Participants were followed for the duration of the procedure and for up to 2 hours after the procedure, an average of 6 hours.</time_frame>
        <population>Full and Safety Analysis Sets. 53.5% of subjects with acute myeloid leukemia (AML), 18.6% of subjects with chronic lymphocytic leukemia, &lt; 10% of subjects with other diagnoses. The WBCD procedure was performed most frequently to treat leukocytosis (44.2%), to prevent tumor lysis syndrome (34.9%), or to treat increased blood viscosity (20.9%).</population>
        <group_list>
          <group group_id="O1">
            <title>Subjects Who Received a Minimum of 1 WBCD Procedure u</title>
            <description>Eligible subjects had received a minimum of 1 WBCD procedure using the Spectra Optia Apheresis System</description>
          </group>
        </group_list>
        <measure>
          <title>Adverse Events</title>
          <population>Full and Safety Analysis Sets. 53.5% of subjects with acute myeloid leukemia (AML), 18.6% of subjects with chronic lymphocytic leukemia, &lt; 10% of subjects with other diagnoses. The WBCD procedure was performed most frequently to treat leukocytosis (44.2%), to prevent tumor lysis syndrome (34.9%), or to treat increased blood viscosity (20.9%).</population>
          <units>Number of subjects with at least 1 AE</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="43"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Patient's WBC Count Pre-depletion Procedure</title>
        <time_frame>Prior to Each Spectra Optia Apheresis Procedure</time_frame>
        <population>Full and Safety Analysis Sets.</population>
        <group_list>
          <group group_id="O1">
            <title>Subjects Who Received a Minimum of 1 WBCD Procedure u</title>
            <description>Eligible subjects had received a minimum of 1 WBCD procedure using the Spectra Optia Apheresis System</description>
          </group>
        </group_list>
        <measure>
          <title>Patient's WBC Count Pre-depletion Procedure</title>
          <population>Full and Safety Analysis Sets.</population>
          <units>cells x 10^9/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="43"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>procedures</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="58"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="243.5" spread="175.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Patient's WBC Count Post-depletion Procedure</title>
        <time_frame>Participants were followed for the duration of the procedure and for up to 2 hours after the procedure, an average of 6 hours.</time_frame>
        <population>Full and Safety Analysis Sets. Data were collected on a total of 58 procedures, however one patient terminated her first procedure prematurely and therefore did not have post-procedure data.</population>
        <group_list>
          <group group_id="O1">
            <title>Subjects Who Received a Minimum of 1 WBCD Procedure u</title>
            <description>Eligible subjects had received a minimum of 1 WBCD procedure using the Spectra Optia Apheresis System</description>
          </group>
        </group_list>
        <measure>
          <title>Patient's WBC Count Post-depletion Procedure</title>
          <population>Full and Safety Analysis Sets. Data were collected on a total of 58 procedures, however one patient terminated her first procedure prematurely and therefore did not have post-procedure data.</population>
          <units>cells x 10^9/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="43"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>procedure</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="57"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="119.5" spread="156.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Patient's Platelet Count Pre-depletion Procedure</title>
        <time_frame>Prior to Each Spectra Optia Apheresis Procedure</time_frame>
        <population>Full and Safety Analysis Sets.</population>
        <group_list>
          <group group_id="O1">
            <title>Subjects Who Received a Minimum of 1 WBCD Procedure u</title>
            <description>Eligible subjects had received a minimum of 1 WBCD procedure using the Spectra Optia Apheresis System</description>
          </group>
        </group_list>
        <measure>
          <title>Patient's Platelet Count Pre-depletion Procedure</title>
          <population>Full and Safety Analysis Sets.</population>
          <units>cells x 10^3/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="43"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>procedures</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="58"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88.1" spread="75.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Patient's Platelet Count Post-depletion Procedure</title>
        <time_frame>Participants were followed for the duration of the procedure and for up to 2 hours after the procedure, an average of 6 hours.</time_frame>
        <population>Full and Safety Analysis Sets. Data were collected on a total of 58 procedures, however one patient terminated her first procedure prematurely and therefore did not have post-procedure data.</population>
        <group_list>
          <group group_id="O1">
            <title>Subjects Who Received a Minimum of 1 WBCD Procedure u</title>
            <description>Eligible subjects had received a minimum of 1 WBCD procedure using the Spectra Optia Apheresis System</description>
          </group>
        </group_list>
        <measure>
          <title>Patient's Platelet Count Post-depletion Procedure</title>
          <population>Full and Safety Analysis Sets. Data were collected on a total of 58 procedures, however one patient terminated her first procedure prematurely and therefore did not have post-procedure data.</population>
          <units>cells x 10^3/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="43"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>procedures</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="57"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59.5" spread="53.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Whole Blood Processed (mL)</title>
        <description>volume of patient's blood processed during the apheresis procedure</description>
        <time_frame>Participants were followed for the duration of the procedure and for up to 2 hours after the procedure, an average of 6 hours.</time_frame>
        <population>Full and Safety Analysis Sets</population>
        <group_list>
          <group group_id="O1">
            <title>Subjects Who Received a Minimum of 1 WBCD Procedure u</title>
            <description>Eligible subjects had received a minimum of 1 WBCD procedure using the Spectra Optia Apheresis System</description>
          </group>
        </group_list>
        <measure>
          <title>Whole Blood Processed (mL)</title>
          <description>volume of patient's blood processed during the apheresis procedure</description>
          <population>Full and Safety Analysis Sets</population>
          <units>mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="43"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>procedures</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="58"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11,394.6" spread="4009.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Post-Hoc</type>
        <title>Total Blood Volumes (TBV) Processed</title>
        <description>Number of times the patient's TBV was processed during the apheresis procedure based on the patient's estimated TBV (Estimated by Nadler's formula for total blood volume of a human being based on gender, height, and weight).</description>
        <time_frame>Post each Spectra Optia Apheresis Procedure</time_frame>
        <population>Full and Safety Analysis Sets</population>
        <group_list>
          <group group_id="O1">
            <title>Subjects Who Received a Minimum of 1 WBCD Procedure u</title>
            <description>Eligible subjects had received a minimum of 1 WBCD procedure using the Spectra Optia Apheresis System</description>
          </group>
        </group_list>
        <measure>
          <title>Total Blood Volumes (TBV) Processed</title>
          <description>Number of times the patient's TBV was processed during the apheresis procedure based on the patient's estimated TBV (Estimated by Nadler's formula for total blood volume of a human being based on gender, height, and weight).</description>
          <population>Full and Safety Analysis Sets</population>
          <units>TBV</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="43"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>procedures</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="58"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.5" spread="0.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Average Inlet Flow Rate</title>
        <time_frame>Participants were followed for the duration of the procedure and for up to 2 hours after the procedure, an average of 6 hours.</time_frame>
        <population>Full and Safety Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>Subjects Who Received a Minimum of 1 WBCD Procedure u</title>
            <description>Eligible subjects had received a minimum of 1 WBCD procedure using the Spectra Optia Apheresis System</description>
          </group>
        </group_list>
        <measure>
          <title>Average Inlet Flow Rate</title>
          <population>Full and Safety Analysis Set</population>
          <units>mL/min</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="43"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>procedures</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="58"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51.1" spread="12.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Procedure Duration</title>
        <time_frame>Participants were followed for the duration of the procedure and for up to 2 hours after the procedure, an average of 6 hours.</time_frame>
        <population>Full and Safety Analysis Sets</population>
        <group_list>
          <group group_id="O1">
            <title>Subjects Who Received a Minimum of 1 WBCD Procedure u</title>
            <description>Eligible subjects had received a minimum of 1 WBCD procedure using the Spectra Optia Apheresis System</description>
          </group>
        </group_list>
        <measure>
          <title>Procedure Duration</title>
          <population>Full and Safety Analysis Sets</population>
          <units>minutes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="43"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>procedures</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="58"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="231.8" spread="92.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Platelet Change (% Change)</title>
        <description>% change in patient's pre and post-depletion procedure platelet counts</description>
        <time_frame>Participants were followed for the duration of the procedure and for up to 2 hours after the procedure, an average of 6 hours.</time_frame>
        <population>Data were collected on a total of 58 procedures, however one patient terminated her first procedure prematurely and therefore did not have post-procedure data.</population>
        <group_list>
          <group group_id="O1">
            <title>Subjects Who Received a Minimum of 1 WBCD Procedure u</title>
            <description>Eligible subjects had received a minimum of 1 WBCD procedure using the Spectra Optia Apheresis System</description>
          </group>
        </group_list>
        <measure>
          <title>Platelet Change (% Change)</title>
          <description>% change in patient's pre and post-depletion procedure platelet counts</description>
          <population>Data were collected on a total of 58 procedures, however one patient terminated her first procedure prematurely and therefore did not have post-procedure data.</population>
          <units>percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="43"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>procedures</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="57"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-20.7" spread="62.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Waste Bag Volume</title>
        <description>Volume of the depletion product</description>
        <time_frame>Post each Spectra Optia Apheresis Procedure</time_frame>
        <population>Full and Safety Analysis Sets</population>
        <group_list>
          <group group_id="O1">
            <title>Subjects Who Received a Minimum of 1 WBCD Procedure u</title>
            <description>Eligible subjects had received a minimum of 1 WBCD procedure using the Spectra Optia Apheresis System</description>
          </group>
        </group_list>
        <measure>
          <title>Waste Bag Volume</title>
          <description>Volume of the depletion product</description>
          <population>Full and Safety Analysis Sets</population>
          <units>mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="43"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>procedures</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="58"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1371.2" spread="896.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse event data (including serious adverse events [SAEs]) were collected from the time of the start of the WBCD procedure through 2 hours post-procedure.</time_frame>
      <desc>Adverse events were graded using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE), version 4.03, and coded using the Medical Dictionary for Regulatory Activities (MedDRA®, version 17.0).</desc>
      <group_list>
        <group group_id="E1">
          <title>Subjects Who Received a Minimum of 1 WBCD Procedure u</title>
          <description>Eligible subjects had received a minimum of 1 WBCD procedure using the Spectra Optia Apheresis System</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA®, version 17</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>hypocalcemia</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Platelet count decreased</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Hypokalemia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Study Site reserves the right to publish the results of its work on the Study. The timing of publication however shall not exceed the 6 months after completion of the Study. Study Site and the PI agree to submit copies of any manuscript/abstract proposed for publication to Sponsor at least 30 days in advance of the presentation. Sponsor may require the delay of publication for no longer than 90 days for the purpose of filing patent applications.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Raymond P. Goodrich, PhD, VP, Scientific and Clinical Affairs; Chief Science Officer-BBT</name_or_title>
      <organization>Terumo BCT</organization>
      <phone>303-231-4357</phone>
      <email>ray.goodrich@terumobct.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

